Skip to main content
Premium Trial:

Request an Annual Quote

$50 Million Burrill-Bayer VC Fund Now to Close By End-2002

NEW YORK, Aug. 29 - A biotech venture capital fund launched in January by Burrill & Company and Bayer Diagnostics has secured half of the $50 million originally slated to close by June.

 

Steven Burrill, CEO of the eponymous merchant bank, today said the fund is now expected to close by the end of the year.

 

Bayer Diagnostic and Burrill & Company said they formed the fund, called the Burrill Diagnostics Capital Fund, to back new pharmacogenomic- and proteomic-based diagnostic research.

  

The fund will focus on high-growth areas such as device miniaturization, pharmacogenomic testing, and non-invasive testing, Bayer Diagnostics president Rolf Classon said in a statement in January.

 

Burrill and Bayer also mentioned as targets technologies that allow for disease-susceptibility genotyping and tools for genetic stratification of patients in clinical trials.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.